<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<atom:link href="http://rss.en.redtram.com/catalogue/world/critical-care-medicine-and-anesthesiology/feed.xml" rel="self" type="application/rss+xml" />
<title>RedTram News Search Engine | News on &quot;Critical Care Medicine &amp; Anesthesiology&quot;  everywhere</title>
<link>http://en.redtram.com/</link>
<description>News on &quot;Critical Care Medicine &amp; Anesthesiology&quot;  everywhere</description>
<copyright>Copyright (c) 2009 RedTram. All rights reserved.</copyright>
<webMaster>webmaster@redtram.com (RedTram)</webMaster>
<language>en</language>
<lastBuildDate>Sat, 28 Nov 2009 05:38:51 GMT</lastBuildDate>
<ttl>300</ttl>
<image>
<title>RedTram News Search Engine | News on &quot;Critical Care Medicine &amp; Anesthesiology&quot;  everywhere</title>
<width>100</width>
<height>50</height>
<link>http://en.redtram.com/</link>
<url>http://img.en.redtram.com/rsslogo.gif</url>
</image>
<item>
<category>148874 | GSK &amp; Adolor Complete Enrolment Of Pivotal Entereg (alvimopan) Clinical Studies To Treat GI Side Effects Of Opioids Used For Persistent Pain</category>
<title>GSK &amp; Adolor Complete Enrolment Of Pivotal Entereg (alvimopan) Clinical Studies To Treat GI Side Effects Of Opioids Used For Persistent Pain</title>
<link>http://en.redtram.com/go/43286579/top100/</link>
<source url="http://en.redtram.com/sources/43286579/">43286579</source>
<description>GlaxoSmithKline (NYSE: GSK) and Adolor Corporation (Nasdaq: ADLR) announced today that GSK has completed enrolment of the Phase 3 clinical programme to evaluate the efficacy and safety of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal adverse</description>
<pubDate>Sat, 15 Apr 2006 07:20:06 GMT</pubDate>
<guid isPermaLink="true">http://en.redtram.com/go/43286579/top100/</guid>
</item>
</channel>
</rss>
